Management of solid tumours in organ-transplant recipients

Lancet Oncology

Volumn 8, Issue 10, 2007, Pages 921-932

  Ajithkumar, Thankamma V ^a   Parkinson, Christine A ^b   Butler, Andrew ^b   Hatcher, Helen M ^b  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ANUS CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CANCER INCIDENCE; CARCINOGENESIS; CEREBRAL BLINDNESS; COLORECTAL CANCER; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG METABOLISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GRAFT REJECTION; HEAD AND NECK CANCER; HEART TRANSPLANTATION; HUMAN; INFECTION; INTESTINE TRANSPLANTATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; LUNG CANCER; LUNG TOXICITY; LUNG TRANSPLANTATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; RECURRENT CANCER; RETICULOENDOTHELIAL NEOPLASM; REVIEW; SKIN CANCER; SKIN ULCER; SOLID TUMOR; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER;

HUMANS; IMMUNE TOLERANCE; INCIDENCE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; ORGAN TRANSPLANTATION; TISSUE DONORS;

EID: 34748812496     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70315-7     Document Type: Review

References (81)

1. Buell J., Gross T., and Woodle E. Malignancy after transplantation. Transplantation 80 2 Suppl (2005) S254-S264
2. LaCasce A. Post-transplant lymphoproliferative disorders. Oncologist 11 (2006) 674-680
3. Taylor A., Marcus R., and Bradley J. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56 (2005) 155-167
4. Adami J., Gabel H., Lindelof B., et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 89 (2003) 1221-1227
5. Kasiske B., Snyder J., Gilbertson D., and Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 4 (2004) 905-913
6. Ramsay H., Fryer A., Hawley C., Smith A., Nicol D., and Harden P. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 49 (2003) 397-406
7. Harwood C., Proby C., McGregor J., Sheaff M., Leigh I., and Cerio R. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. J Am Acad Dermatol 54 (2006) 290-300
8. Berg D., and Otley C. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 47 (2002) 1-17
9. Moosa M. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience. QJM 98 (2005) 205-214
10. Ahmed Z., Marshall M., Kucharczuk J., Kaiser L., and Shrager J. Lung cancer in transplant recipients: a single-institution experience. Arch Surg 139 (2004) 902-906
11. de Perrot M., Fischer S., Waddell T., et al. Management of lung transplant recipients with bronchogenic carcinoma in the native lung. J Heart Lung Transplant 22 (2003) 87-89
12. Stewart T., Tsai S., Grayson H., Henderson R., and Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346 (1995) 796-798
13. Oruc M., Soran A., Jain A., Wilson J., and Fung J. De novo breast cancer in patients with liver transplantation: University of Pittsburgh's experience and review of the literature. Liver Transpl 10 (2004) 1-6
14. Buell J., Trofe J., Hanaway M., et al. Immunosuppression and merkel cell cancer. Transplant Proc 34 (2002) 1780-1781
15. Vera A., Gunson B., Ussatoff V., et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 75 (2003) 1983-1988
16. Saidi R., Dudrick P., and Goldman M. Colorectal cancer after renal transplantation. Transplant Proc 35 (2003) 1410-1412
17. Ampil F., Ghali G., Munker R., and Kimm D. De novo head and neck carcinoma in transplant recipients: preliminary results of management. J Oral Maxillofac Surg 64 (2006) 1081-1085
18. Muruve N., and Shoskes D. Genitourinary malignancies in solid organ transplant recipients. Transplantation 80 (2005) 709-716
19. US Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in United States (2003), National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD
20. Swindle P., Falk M., Rigby R., Petrie J., Hawley C., and Nicol D. Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. Br J Urol 81 (1998) 229-233
21. Euvrard S., Kanitakis J., Chardonnet Y., et al. External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment. Arch Dermatol 133 (1997) 175-178
22. Wong G, Howard K, Craig J, McDonald S, Chapman J. 29th report-Australia and New Zealand Dialysis and Transplant Registry-2006. McDonald S, Chang S, Excell L, eds. 2006: 138-142.
23. Vajdic C., McDonald S., McCredie M., et al. Cancer incidence before and after kidney transplantation. JAMA 296 (2006) 2823-2831
24. Sanchez W., Talwalkar J., and Gores G. "Will all liver transplantation patients eventually die from cancer?". J Hepatol 44 (2006) 13-18
25. Benlloch S., Prieto M.B., et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?. Am J Transplant 4 (2004) 596-604
26. Jain A., Yee L., Nalesnik M., et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 66 (1998) 1193-1200
27. Haagsma E., Hagens V., Schaapveld M., et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 34 (2001) 84-91
28. Pierson III R. Lung transplantation: current status and challenges. Transplantation 81 (2006) 1609-1615
29. Ippoliti G., Rinaldi M., Pellegrini C., and Vigano M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol 56 (2005) 101-113
30. El-Hamamsy I., Stevens L., Carrier M., et al. Incidence and prognosis of cancer following heart transplantation using RATG induction therapy. Transpl Int 18 (2005) 1280-1285
31. Caforio A., Gambino A., Piaserico S., et al. De novo noncutaneous malignancies in heart transplantation: a single-centre 15-year experience and risk factor analysis. Transplant Proc 33 (2001) 3658-3659
32. Rinaldi M., Pellegrini C., D'Armini A., et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 19 (2001) 696-701
33. Goldstein D., Williams D., Oz M., Weinberg A., Rose E., and Michler R. De novo solid malignancies after cardiac transplantation. Ann Thorac Surg 60 (1995) 1783-1789
34. Potaris K., Radovancevic B., Thomas C., et al. Lung cancer after heart transplantation: a 17-year experience. Ann Thorac Surg 79 (2005) 980-983
35. Anyanwu A., Townsend E., Banner N., Burke M., Khaghani A., and Yacoub M. Primary lung carcinoma after heart or lung transplantation: management and outcome. J Thorac Cardiovasc Surg 124 (2002) 1190-1197
36. Abu-Elmagd K., Zak M., Stamos J., et al. De novo malignancies after intestinal and multivisceral transplantation. Transplantation 77 (2004) 1719-1725
37. Geissler E., and Schlitt H. The relation between immunosuppressive agents and malignancy. Curr Opinion in Organ Transpl 9 (2004) 394-399
38. Benisovich V., Silverman l., Slifkin R., Stone N., and Cohen E. Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Cancer 77 (1996) 160-163
39. Sanchez-Fructuoso A., Conesa J., Perez Flores I., et al. Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc 38 (2006) 2451-2452
40. Ciancio G., Antun R., Norberg D., Mitrani A., de Marchena E., and Soloway M. Prostate cancer after heart transplantation. J Urol 153 (1995) 158-160
41. Yiou R., Salomon L., Colombel M., Patard J., Chopin D., and Abbou C. Perineal approach to radical prostatectomy in kidney transplant recipients with localized prostate cancer. Urology 53 (1999) 822-824
42. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
43. Mouzin M., Bachaud J., Kamar N., et al. Three-dimensional conformal radiotherapy for localized prostate cancer in kidney transplant recipients. Transplantation 78 (2004) 1496-1500
44. McIntyre J., Eifel P., Levenback C., et al. Ureteral stricture as a late complication of radiotherapy for stage IB carcinoma of the uterine cervix. Cancer 75 (1995) 836-843
45. Dahl O., Vagstad G., and Iversen B. Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncol 35 (1996) 759-761
46. Lindley C., Gordon T., and Tremont S. Cisplatin-based chemotherapy in a renal transplant recipient. Cancer 68 (1991) 1113-1117
47. Vogelzang N. Cisplatin-based chemotherapy in a renal transplant recipient. Cancer 69 (1992) 3015-3016
48. Vogelzang N. Cisplatin and etoposide for metastatic testis cancer in a renal transplant recipient. J Urol 143 (1990) 1235-1236
49. Osiason A., and Polackwich R. Curative, platinum-based cytoxic drug therapy in a renal transplant recipient with metastatic testicular cancer. Cancer 58 (1986) 850-851
50. Droz J., Chailley J., and Kreis H. Germinal cell tumors of the testis (GCTT) in renal transplanted patients (RTP): report of two cases. Prog Clin Biol Res 203 (1985) 685-686
51. Frantz P., Luciani J., Khoury S., and Chatelain C. Testicular cancer in a renal transplant patient. Prog Clin Biol Res 203 (1985) 681-683
52. de Bono J., Fraser J., Lee F., et al. Metastatic extragonadal seminoma associated with cardiac transplantation. Ann Oncol 11 (2000) 749-752
53. Srinivas V., Deshmukh R., Shah B., and Kapadia A. Radical cystectomy for invasive squamous cell bladder cancer in a renal transplant patient. Urol Int 51 (1993) 167-170
54. Luftner D., Flath B., Akrivakis C., et al. Feasibility of dose-intensified paclitaxel after chemotherapy-induced renal insufficiency in a patient with renal transplantation. Eur J Cancer 35 (1999) 325
55. Teneriello M., Farley J., Parker M., et al. Management of advanced ovarian epithelial cancer in the renal transplant patient. Gynecol Oncol 50 (1993) 374-378
56. Cescon M., Grazi G., Assietti R., et al. Embryonal rhabdomyosarcoma of the orbit in a liver transplant recipient. Transpl Int 16 (2003) 437-440
57. Plunkett T., Hanby A., Miles D., and Ruben R. Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. Ann Oncol 12 (2001) 411-414
58. Gouyette A., Lemoine R., Adhemar J., et al. Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. Cancer Treat Rep 65 (1981) 665-668
59. Fjeldborg P., Sorensen J., and Helkjaer P. The long-term effect of cisplatin on renal function. Cancer 58 (1986) 2214-2217
60. Manetta A., Boyle J., Berman M., et al. Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A Gynecologic Oncology Group Study. Cancer 73 (1994) 196-199
61. Bodvarsson S., Burlingham W., Kusaka S., et al. Donor-derived small cell lung carcinoma in a kidney transplant recipient. Cancer 92 (2001) 2429-2434
62. Fishmna J., and Rubin R. Infection in organ-transplant recipients. N Engl J Med 338 (1998) 1741-1751
63. Duncan M., and Wilkes D. Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections. Proc Am Thorac Soc 2 (2005) 449-455
64. Electronic medicines compendium. http://www.emc.medicines.org.uk (accessed Sept 17, 2007).
65. Thomson Healthcare. http://www.micromedex.com (accessed Sept 17, 2007).
66. Killenberg P. Drug interactions with commonly used immunosuppressive agents. In: Killenberg P., and Clavien P. (Eds). Medical care of the liver transplant patient: total pre-, intra- and post-operative management (2006), Blackwell Science Inc, Massachussetts 522-535
67. Go R., and Adjei A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17 (1999) 409-422
68. Aapro M., Cameron D., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 (2006) 2433-2453
69. Veness M., and Harris D. Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers. Australas Radiol 51 (2007) 12-20
70. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
71. Buell J., Hanaway M., Trofe J., et al. De novo breast cancer in renal transplant recipients. Transplant Proc 34 (2002) 1778-1779
72. Matzkies F., Tombach B., Dietrich M., et al. MVAC-therapy for advanced urothelial carcinoma in an anuric renal transplant recipient. Nephrol Dial Transplant 15 (2000) 110-112
73. Whang M., Geffner S., Khachikian Z., Kumar A., Bonomini L., and Mulgaonkar S. Renal transplantation and prostate cancer: guidelines for screening and treatment. Transplant Proc 34 (2002) 3196-3199
74. Kasiske B., Vazquez M., Harmon W., et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11 suppl 15 (2000) S1-S86
75. EBPG Expert Group on Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant 17 suppl 4 (2002) 32 34-36.
76. Campistol J., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
77. Myron Kauffman H., McBride M., Cherikh W., Spain P., Marks W., and Roza A. Transplant tumor registry: donor related malignancies. Transplantation 74 (2002) 358-362
78. Buell J., Beebe T., Gross T., et al. United network for organ sharing publication on scientific registry of transplant recipients central nervous system donor cancer transmission data. Transplantation 79 (2005) 623
79. Sheil A. Donor-derived malignancy in organ transplant recipients. Transplant Proc 33 (2001) 1827-1829
80. Morath C., Mueller M., Goldschmidt H., Schwenger V., Opelz G., and Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol 15 (2004) 1582-1588
81. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 2 (1997) 14-17